Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Binghe Xu

Showing results (41-50 of 406) with videos related to

Pageof 41
Sort By:
Cancer Biology & Therapy|February 23, 2012
Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxelWeihong Zhao, Yongmei Song, Binghe Xu, et al.
Chinese Journal of Cancer|May 12, 2017
Neuroendocrine carcinoma of the breast: a review of 126 cases in ChinaYiqun Li, Feng Du, Wenjie Zhu, et al.
Journal of Personalized Medicine|February 25, 2023
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant ChemotherapyZhijun Li, Yiqun Han, Jiayu Wang, et al.
Oncotarget|April 7, 2016
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experienceShuping Xu, Mayra Ramos-Suzarte, Xianhong Bai, et al.
Annals of Translational Medicine|January 25, 2021
HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trialsXinghui Li, Songwen Wu, Lijie Zhang, et al.
Holistic Integrative Oncology|July 31, 2023
An appropriate treatment interval does not affect the prognosis of patients with breast CancerWei Gao, Jiaxing Wang, Sifei Yin, et al.
Breast Cancer Research and Treatment|July 6, 2018
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysisJiayu Wang, Binghe Xu, Wenna Wang, et al.
Cancers|December 23, 2022
Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-AnalysisJiani Wang, Yiqun Han, Jiayu Wang, et al.
International Journal of Clinical Oncology|January 18, 2022
The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based studyYiqun Han, Yun Wu, Hangcheng Xu, et al.
Breast Cancer Research and Treatment|November 25, 2018
Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysisJiayu Wang, Binghe Xu, Wenna Wang, et al.
Pageof 41

Showing results (41-50 of 406) with videos related to

Sort By:
Pageof 41
Cancer Biology & Therapy|February 23, 2012
Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxelWeihong Zhao, Yongmei Song, Binghe Xu, et al.
Chinese Journal of Cancer|May 12, 2017
Neuroendocrine carcinoma of the breast: a review of 126 cases in ChinaYiqun Li, Feng Du, Wenjie Zhu, et al.
Journal of Personalized Medicine|February 25, 2023
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant ChemotherapyZhijun Li, Yiqun Han, Jiayu Wang, et al.
Oncotarget|April 7, 2016
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experienceShuping Xu, Mayra Ramos-Suzarte, Xianhong Bai, et al.
Annals of Translational Medicine|January 25, 2021
HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trialsXinghui Li, Songwen Wu, Lijie Zhang, et al.
Holistic Integrative Oncology|July 31, 2023
An appropriate treatment interval does not affect the prognosis of patients with breast CancerWei Gao, Jiaxing Wang, Sifei Yin, et al.
Breast Cancer Research and Treatment|July 6, 2018
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysisJiayu Wang, Binghe Xu, Wenna Wang, et al.
Cancers|December 23, 2022
Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-AnalysisJiani Wang, Yiqun Han, Jiayu Wang, et al.
International Journal of Clinical Oncology|January 18, 2022
The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based studyYiqun Han, Yun Wu, Hangcheng Xu, et al.
Breast Cancer Research and Treatment|November 25, 2018
Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysisJiayu Wang, Binghe Xu, Wenna Wang, et al.
Pageof 41